Benzinga··NaTeva Bets $700M on Emalex to Bolster Neuroscience Portfolio With First-in-Class Tourette Drug
Teva acquires Emalex Biosciences for $700M upfront plus $200M in milestones for first-in-class Tourette syndrome therapy, closing by Q3 2026.
TEVAacquisitionNDA submission